Safety and Feasibility of Infusing <i>Ex Vivo</i> Expanded Allogeneic Canine Natural Killer Cells for the Treatment of Metastatic Solid Tumors.

ABSTRACT:

Background

Companion canines need advances in therapeutic options for solid tumor malignancies. Prior studies established feasibility of autologous natural killer (NK) cell infusions in canines with solid tumors; however, autologous products are limited by dysfunctional immunity and a manufacturing process that delays care. Allogeneic NK cells offer the possibility of "off-the-shelf" therapy to be administered from healthy donors.

Methods

Peripheral blood mononuclear cells (PBMCs) were isolated from healthy canine donors via density gradient separation. NK cells were expanded with recombinant human IL-2 and canine IL-21 with the addition of K562 feeder cells transfected with CD137 ligand and membrane bound human IL-15. Additional experiments included IL-12 in the expansions.

SUBMITTER: Weisnicht AM 

PROVIDER: S-EPMC13041853 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature